MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2025.01.883

Медицинская библиотека · Transplantation and cellular therapy · 2025

Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation.

Kawamura Shunto, Fujiwara Shin-Ichiro, Kimura Shun-Ichi, Takeshita Junko, Nakasone Hideki, Yoshimura Kazuki, Nakata Yuya, Ishikawa Takuto, Matsuoka Akari, Meno Tomohiro, Nakamura Yuhei, Kawamura Masakatsu, Yoshino Nozomu, Misaki Yukiko, Gomyo Ayumi, Kusuda Machiko, Murahashi Rui, Umino Kento, Minakata Daisuke, Ashizawa Masahiro, Yamamoto Chihiro, Hatano Kaoru, Sato Kazuya, Ohmine Ken, Kako Shinichi, Kanda Yoshinobu

СтатьяПеревод в очереди

Аннотация

We previously reported that the area under the curve of log-transformed cytomegalovirus antigenemia (CMV-AUC) until 100 days after allogeneic hematopoietic cell transplantation (allo-HCT) was associated with an increased risk of non-relapse mortality. We applied a risk-adapted letermovir (LTV) prophylaxis strategy guided by a risk score that predicts a higher CMV-AUC. First, we retrospectively analyzed 278 allo-HCT recipients between 2007 and 2017 (Period 1). We scored risk factors for higher CMV-AUC by odds ratios: malignant lymphoma including adult T cell leukemia/lymphoma (1 point), an unrelated or haploidentical donor (1 point), and recipient/donor CMV serostatus (+/+; 2 points, +/-; 3 points). We have administered LTV to patients with a total score of ≥ 4 points. We then focused on 143 patients who underwent allo-HCT when we applied this strategy (Period 2). Forty patients (28%) in Period 2 received LTV prophylaxis. Two patients (5.4%) exhibited higher CMV-AUC among 37 patients in the higher-risk group (≥ 4 points). However, as many as 33% of the patients with 3 points in Period 2 experienced higher CMV-AUC. Notably, in the lower-risk patients of Period 2, 68% of patients who received systemic steroids for acute graft-versus-host-disease (GVHD) developed higher CMV-AUC. Our risk-adapted LTV prophylaxis strategy effectively prevented higher CMV-AUC in the higher-risk group and reduced the use of LTV. Additionally, including the use of systemic steroids for acute GVHD in this risk-adapted approach is preferable.

Для цитирования: Kawamura Shunto, Fujiwara Shin-Ichiro, Kimura Shun-Ichi, Takeshita Junko, Nakasone Hideki, Yoshimura Kazuki, Nakata Yuya, Ishikawa Takuto, Matsuoka Akari, Meno Tomohiro, Nakamura Yuhei, Kawamura Masakatsu, Yoshino Nozomu, Misaki Yukiko, Gomyo Ayumi, Kusuda Machiko, Murahashi Rui, Umino Kento, Minakata Daisuke, Ashizawa Masahiro, Yamamoto Chihiro, Hatano Kaoru, Sato Kazuya, Ohmine Ken, Kako Shinichi, Kanda Yoshinobu. Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation.. Transplantation and cellular therapy. 2025. DOI: 10.1016/j.jtct.2025.01.883.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.